Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, non-randomized, observational, pre-clinical validation study. Pierian Biosciences is utilizing ChemoINTEL assay measured in vitro cytotoxic drug induced apoptosis and cell death in isolated fresh human tumour cells from patients with colorectal cancer (CRC) to predict a patient's tumour's sensitivity to specific chemotherapy drugs using the ChemoINTEL unified algorithm. Eligible patients will be assigned to one of three groups depending on the stage of disease : Group 1: Patients who have colorectal cancer and are referred for adjuvant chemotherapy after MDT discussion. Group 2: Patients with stage II colorectal cancer with high risk features not referred for adjuvant chemotherapy (at risk of relapse) Group 3: Patients with locally advanced rectal cancer who have had a complete response to chemoradiotherapy (research objective). At least one solid tumour specimen and adjacent normal tissue will be sent to Pierian Biosciences Laboratory in Liverpool, UK along with an optional 10-20ml blood sample and The Pierian Biosciences laboratory staff will conduct the ChemoINTEL and ImmunoINTEL assays blinded to all specimen and clinical information except the tumor type (e.g. Colon Cancer or Rectal Cancer), Specimen ID, and specimen collection date and time. Results of the assay will NOT be shared with clinical sites. Samples from group 3 will be provided if patients undergo surgical resection.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony diagnoza raka jelita grubego (rak okrężnicy lub odbytnika)
- •Planowana chemioterapia - co najmniej 6 cykli standardowych leków chemioterapeutycznych
- •Pobrany fragment guza (przedtem przeprowadzona operacja lub biopsja)
- •Podpisana zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Brak podpisanej zgody na uczestnictwo w badaniu
- •Obecność innego rodzaju nowotworu niż rak jelita grubego
- •Pacjent nie będzie otrzymywać standardowej chemioterapii
- •Pobrany fragment guza nie zawiera wystarczającej ilości żywych komórek do analizy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Locations (1)
Liverpool University Hospital NHS Foundation Trust
Liverpool, United Kingdom
Trial contact
Norman B Purvis, PhD
Robert Henry
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.